Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 14/20 | 0.63 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903775 | 0.92 | KIT (0.73) | KITDYRK1APIK3CASLC2A1AAK1 | |
| SCHEMBL7907903 | 0.89 | KIT (0.70) | KITMAP3K11DYRK1APIK3CASLC2A1 | |
| SCHEMBL7910174 | 0.85 | MAP3K11 (0.60) | KITMAP3K11DYRK1APIK3CASLC2A1 | |
| SCHEMBL7906551 | 0.84 | KIT (0.57) | KITMAP3K11DYRK1ANTRK1PIK3CA | |
| SCHEMBL7905041 | 0.84 | NTRK1 (0.63) | KITMAP3K11DYRK1ANTRK1PIK3CA | |
| SCHEMBL7910200 | 0.84 | KIT (0.58) | KITDYRK1ANTRK1PIK3CASLC2A1 | |
| SCHEMBL7908343 | 0.83 | MAP4K1 (0.54) | KITMAP3K11NTRK1PIK3CAAAK1 | |
| SCHEMBL7908989 | 0.83 | MAP3K11 (0.63) | KITMAP3K11DYRK1ANTRK1PIK3CA | |
| SCHEMBL12066048 | 0.83 | MAP4K1 (0.65) | KITMAP3K11DYRK1ANTRK1LRRK2 | |
| SCHEMBL7905848 | 0.81 | KIT (0.60) | KITDYRK1APIK3CASLC2A1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |